Raffaele Colombo/LinkedIn
Nov 13, 2024, 23:35
Raffaele Colombo: New BLA submitted for patients with EGFR-m NSCLC
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared an article on X:
“Dato-DXd previous BLA (based on TROPION-Lung01) voluntary withdrew and new BLA (based on TROPION-Lung05) submitted for patients with EGFR-m NSCLC!!”
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advancing the treatment landscape for various diseases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 23:35
Nov 13, 2024, 23:33
Nov 13, 2024, 23:28
Nov 13, 2024, 23:26
Nov 13, 2024, 23:22
Nov 13, 2024, 23:18
Nov 13, 2024, 19:25